We believe A.I. has the power to help Doctors discover and diagnose skin cancer, both easily and effectively.
Kāhu A.I. technology is being developed in collaboration with Molemap Ltd, to help Doctors discover and diagnose skin cancer.
Combining one of the largest known databases of skin lesions and next-generation technology, we're designing products with patient safety at the heart of what we do.
Our clinical program and medical advisory board have a robust clinical roadmap to ensure our technologies are proven as safe and effective.
We work closely with physicians in North America, Australia & New Zealand to ensure our products are not only safe and effective, but fit-for-purpose and easy to use.
Adults in the U.S., during 2007–2011 were treated for skin cancer each year. (7)
Average annual total treatment costs during 2007-2011. (8)
Estimated annual costs associated with lost workdays and restricted-activity days for NMSC and melanoma. (9)
Whilst COVID-19 has impacted healthcare systems around the world, skin cancer remains ever present. The leading Australasian specialists at the frontline of the battle, MoleMap, figured they could do better. (1)Learn more
Unlike other technologies in this space, Kāhu technology is being developed by leveraging MoleMap’s world-leading database of high-quality dermatological images. (22)
We can confidently say that Kāhu will have seen more skin lesions and melanomas than most healthcare professionals.
Kāhu A.I. is a clinical decision support tool and is not intended to replace the clinical decisions made by healthcare professionals.It is intended to give the clinicians more information about skin lesions to help them make more informed decisions. Just like a blood test or an X-ray might.